Leerink Partnrs Boosts Earnings Estimates for Exact Sciences

Exact Sciences Co. (NASDAQ:EXAS) – Equities research analysts at Leerink Partnrs raised their Q3 2025 earnings per share estimates for Exact Sciences in a report issued on Thursday, February 20th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings per share of $0.12 for the quarter, up from their previous estimate of $0.09. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.59) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.27 EPS, Q2 2026 earnings at $0.22 EPS, FY2026 earnings at $0.93 EPS and FY2027 earnings at $1.54 EPS.

Several other equities analysts have also commented on the company. Robert W. Baird cut their price target on Exact Sciences from $70.00 to $67.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Citigroup cut their price target on Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Bank of America cut their price target on Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday. Piper Sandler cut their price target on Exact Sciences from $85.00 to $75.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Finally, Craig Hallum cut their price target on Exact Sciences from $82.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $72.06.

Exact Sciences Stock Down 0.5 %

NASDAQ:EXAS opened at $49.26 on Friday. Exact Sciences has a twelve month low of $40.62 and a twelve month high of $79.62. The company has a market cap of $9.12 billion, a price-to-earnings ratio of -8.84 and a beta of 1.24. The stock has a fifty day simple moving average of $54.91 and a 200-day simple moving average of $59.99. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 37.29%. The business had revenue of $713.42 million during the quarter, compared to the consensus estimate of $701.45 million.

Institutional Investors Weigh In On Exact Sciences

Large investors have recently modified their holdings of the business. Thompson Investment Management Inc. grew its stake in shares of Exact Sciences by 17.8% during the fourth quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company’s stock worth $13,585,000 after acquiring an additional 36,505 shares during the last quarter. WCM Investment Management LLC grew its stake in shares of Exact Sciences by 1,153.2% during the third quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company’s stock worth $12,388,000 after acquiring an additional 172,821 shares during the last quarter. Simplify Asset Management Inc. grew its stake in shares of Exact Sciences by 67.5% during the third quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company’s stock worth $1,994,000 after acquiring an additional 11,800 shares during the last quarter. Zacks Investment Management acquired a new stake in shares of Exact Sciences during the third quarter worth about $2,083,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Exact Sciences by 59.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company’s stock worth $22,868,000 after purchasing an additional 125,192 shares during the period. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.